Recently, BD (Becton, Dickinson and Company) announced the appointment of Puneet Sarin as the global president of BD Bioscience, which took effect on the same day.

Recently, the 2019 Siemens Pharmaceutical Industry Summit was successfully held in Chengdu. During the conference, the world's leading biopharmaceutical industry supplier Sartorius Stedim Biotech and Siemens announced ...

Personalis announced recently that it has priced its initial public offering of around 7.9 million shares of common stock at $17 per share.

Amoy Diagnostics, Premia Holdings, and Loxo Oncology recently announced a partnership aimed at genetic screening of patients for a targeted cancer therapy.

Almac Diagnostic Services recently announced that it has received CE marking for a next-generation sequencing-based diagnostic assay that will be used to ...

Thermo Fisher Scientific recently announced a number of new partnerships in conjunction with the annual American Society for Mass Spectrometry Conference in Atlanta.

Horizon Therapeutics has partnered with Invitae for its urea cycle disorder genetic (UCD) testing program, through which individuals who may have the rare genetic condition and their family members will receive testing at no charge.

Becton Dickinson reported today that its fiscal second quarter revenues decreased approximately 1 percent year over year.

Hologic announced today that the US Food and Drug Administration has cleared two of its infectious disease assays for common causes of a condition called vaginitis.

Roche today announced the CE-IVD marking of its Cobas MTB-RIF/INH test that detects mutations associated with resistance to the antibiotics rifampicin and isoniazid within tuberculosis DNA.

Investment Plan for Europe: Mobidiag secures EUR 25 million from EIB Funds will be used to accelerate the development and commercialisation of in vitro diagnostic solutions for infectious diseases.

Hologic reported after the close of the market on Wednesday that its fiscal second quarter revenues rose 4 percent year over year, driven by strong sales in its molecular diagnostics business.

Bio-Techne said today that its 2019 fiscal third quarter revenues rose 13 percent year over year, driven by double-digit organic growth in North America, Europe, and China.

Bio-Rad Laboratories reported after the close of the market Wednesday that its first quarter revenues rose a fraction of a percent year over year, besting Wall Street estimates.

Agilent Technologies reported after the close of the market on Tuesday that its fiscal second quarter revenues rose 3 percent year over year.